Primary antiretroviral drug resistance among patients diagnosed with HIV infection in Gran Canaria (Spain) between 2002 and 2005;Resistencias primarias a los fármacos antirretrovirales en los pacientes diagnosticados de infección por el VIH en Gran Canaria entre los años 2002-2005

Enfermedades Infecciosas y Microbiologia Clinica

Volumn 25, Issue 7, 2007, Pages 437-440

  Oñoro, Mónica Sánchez ^a   Pena López, María José ^a   Santana, Miguel Ángel Cárdenes ^a   Andés, José María Zarzalejos ^a   Campelo, Fernando Artiles ^a  

^a HOSPITAL UNIVERSITARIO DE GRAN CANARIA DR NEGRÍN   (Spain)

Author keywords

Antiretroviral drugs; HIV infection; Primary resistance

Indexed keywords

ANTIRETROVIRUS AGENT; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ANTIBIOTIC RESISTANCE; ARTICLE; BISEXUALITY; CONTROLLED STUDY; DISEASE DURATION; EPIDEMIOLOGICAL DATA; GENE SEQUENCE; GENOTYPE; HOMOSEXUALITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN IMMUNODEFICIENCY VIRUS PREVALENCE; MAJOR CLINICAL STUDY; MULTIDRUG RESISTANCE; PROSPECTIVE STUDY; SPAIN; VIRUS CARRIER; VIRUS DIAGNOSIS; VIRUS MUTATION; VIRUS TYPING;

EID: 34548170913     PISSN: 0213005X     EISSN: 15781852     Source Type: Journal    
DOI: 10.1157/13108707     Document Type: Article

References (14)

1. Little SJ, Holte S, Routy J-P, Daar E, Markowitz M, Collier AC, et al. Antiretroviral-drug resistance among patients recently infected with HIV. N Engl J Med. 2002;347:385-94.
2. Grant RM, Hecht FM, Warmerdam M, Liu L, Liegler T, Petropoulos CJ, et al. Time trends in primary HIV-1 drug resistance among recently infected persons. JAMA. 2002;288:181-8.
3. UK Group on transmitted HIV drug resistance. Time trends in primary resistance to HIV drugs in the United Kingdom: multicentre observational study. BMJ 2005, doi: 10.1136/bmj.38665-534595.55.
4. Wensing AMJ, Van de Vijver DA, Angarano G, Asjö B, Balotta C, Boeri E, et al. Prevalence of drug-resistant HIV-1 variants in untreated individuals in Europe: implications for clinical management. J Infect Dis. 2005;192:958-66.
5. Hecht FM, Grant RM, Petropoulos CJ, Dillon B, Chesney MA, Tian H, et al. Sexual transmision of an HIV-1 variant resistant to multiple reverse-transcriptase and protease inhibitors. N Engl J Med. 1998;339:307-11.
6. Boden D, Hurley A, Zhang L, Cao Y, Guo Y, Jones E, et al. HIV-1 Drug resistance in newly infected individuals. JAMA. 1999;282:1135-41.
7. Little SJ, Daar ES, D'Aquila RT, Keiser PH, Connick E, Whitcomb JM, et al. Reduced antiretroviral drug susceptibility among patients with primary HIV infection. JAMA. 1999;282:1142-9.
8. Gatell JM, Blanco JL, Alcamí J, Antela A, Arrizabalaga J, Casado JL, et al. Documento de consenso de GESIDA sobre la utilización de los estudios de resistencias en la práctica clínica. Enferm Infecc Microbiol Clin. 2001;19:53-60.
9. Hirsch MS, Brun-Vézinet F, Clotet B, Conway B, Kuritzkes DR, D'Aquila RT, et al. Antiretroviral drug resistance testing in adults infected with human immunodeficiency virus type1: 2003 Recommendations of an International AIDS Society-USA Panel. Clin Infect Dis. 2003;37:113-28.
10. Havlir DV, Marchner IC, Hirsch MS, Collier AC, Tebas P, Bassett RL, et al. Maintenance antiretroviral therapies in HIV infected patients with undetectable plasma HIV RNA after triple-drug therapy. AIDS Clinical Trials Group Study 343 team. N Engl J Med. 1998;339:1261-8.
11. Chaix ML, Deschamps D, Harzic M, Schneider V, Deveau C, Tamalet C, et al. Stable prevalence of genotypic drug resistance mutations but increase in non-B virus infection in France. AIDS. 2003;17:2635-43.
12. Oette M, Kaiser R, Däumer M, Petch R, Fätkenheuer G, Carls H, et al. Primary HIV drug resistance and efficacy of first-line antiretroviral therapy guided by resistance testing. J Acquir Immune Defic Syndr. 2006;41:573-81.
13. Guerrero A, Cañizares A, Tomás S, Velasco D, Cartelle M y grupo de estudio para las resistencias primarias del VIH en España. Prevalencia de resistencia a los fármacos antirretrovirales en pacientes españoles infectados por el VIH y sin tratamiento previo. Enferm Infecc Microbiol Clin. 2005;23:605-8.00
14. De Mendoza C, Rodríguez C, Eirós JM, Colomina J, García F, Leiva P, et al. Antiretroviral recommendations may influence the rate of transmisión of drug-resistant HIV type 1. Clin Infect Dis. 2005;41:227-32.